BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ross JS, Waldstreicher J, Bamford S, Berlin JA, Childers K, Desai NR, Gamble G, Gross CP, Kuntz R, Lehman R, Lins P, Morris SA, Ritchie JD, Krumholz HM. Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Sci Data 2018;5:180268. [PMID: 30480665 DOI: 10.1038/sdata.2018.268] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Odufalu F. Editorial: Racial Difference in Efficacy of Golimumab in Ulcerative Colitis. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izac179] [Reference Citation Analysis]
2 Gudi N, Kamath P, Chakraborty T, Jacob AG, Parsekar SS, Sarbadhikari SN, John O. Regulatory Frameworks for Clinical Trial Data Sharing: Scoping Review. J Med Internet Res 2022;24:e33591. [PMID: 35507397 DOI: 10.2196/33591] [Reference Citation Analysis]
3 Gietl AF, Frisoni GB. Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science. Alzheimers Dement 2022. [PMID: 35220681 DOI: 10.1002/alz.12605] [Reference Citation Analysis]
4 Rydzewska LHM, Stewart LA, Tierney JF. Sharing individual participant data: through a systematic reviewer lens. Trials 2022;23. [DOI: 10.1186/s13063-021-05787-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Plana D, Fell G, Alexander BM, Palmer AC, Sorger PK. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nat Commun 2022;13:873. [PMID: 35169116 DOI: 10.1038/s41467-022-28410-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study. BMC Med Res Methodol 2021;21:263. [PMID: 34837957 DOI: 10.1186/s12874-021-01460-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Plott CF, Sharfstein JM. Global Regulatory Agencies and Data Transparency. J Law Med Ethics 2021;49:486-8. [PMID: 34665106 DOI: 10.1017/jme.2021.68] [Reference Citation Analysis]
8 Chen ZH, Lin L, Wu CF, Li CF, Xu RH, Sun Y. Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Commun (Lond) 2021;41:1100-15. [PMID: 34613667 DOI: 10.1002/cac2.12215] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
9 Hodkinson A, Heneghan C, Mahtani KR, Kontopantelis E, Panagioti M. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. BMC Med 2021;19:195. [PMID: 34429113 DOI: 10.1186/s12916-021-02062-w] [Reference Citation Analysis]
10 Vazquez E, Gouraud H, Naudet F, Gross CP, Krumholz HM, Ross JS, Wallach JD. Characteristics of available studies and dissemination of research using major clinical data sharing platforms. Clin Trials 2021;:17407745211038524. [PMID: 34407656 DOI: 10.1177/17407745211038524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ohmann C, Moher D, Siebert M, Motschall E, Naudet F. Status, use and impact of sharing individual participant data from clinical trials: a scoping review. BMJ Open 2021;11:e049228. [PMID: 34408052 DOI: 10.1136/bmjopen-2021-049228] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Ross JS. Covid-19, open science, and the CVD-COVID-UK initiative. BMJ 2021;373:n898. [PMID: 33827892 DOI: 10.1136/bmj.n898] [Reference Citation Analysis]
13 Coetzee T, Ball MP, Boutin M, Bronson A, Dexter DT, English RA, Furlong P, Goodman AD, Grossman C, Hernandez AF, Hinners JE, Hudson L, Kennedy A, Marchisotto MJ, Myers E, Nowell WB, Nosek BA, Sherer T, Shore C, Sim I, Smolensky L, Williams C, Wood J, Terry SF, Matrisian L. Data Sharing Goals for Nonprofit Funders of Clinical Trials. J Particip Med 2021;13:e23011. [PMID: 33779573 DOI: 10.2196/23011] [Reference Citation Analysis]
14 Danchev V, Min Y, Borghi J, Baiocchi M, Ioannidis JPA. Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement. JAMA Netw Open 2021;4:e2033972. [PMID: 33507256 DOI: 10.1001/jamanetworkopen.2020.33972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
15 Li R, Sim I. How Clinical Trial Data Sharing Platforms Can Advance the Study of Biomarkers. J Law Med Ethics 2019;47:369-73. [PMID: 31560635 DOI: 10.1177/1073110519876165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Krumholz HM. Inflection Point: Ideas for Accelerating Breakthroughs and Improving Cardiovascular Health. Circ Cardiovasc Qual Outcomes 2020;13:e007615. [PMID: 33200951 DOI: 10.1161/CIRCOUTCOMES.120.007615] [Reference Citation Analysis]
17 Li R, Wood J, Baskaran A, Neumann S, Graham E, Levenstein M, Sim I. Timely access to trial data in the context of a pandemic: the time is now. BMJ Open 2020;10:e039326. [PMID: 33122319 DOI: 10.1136/bmjopen-2020-039326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Rekkas A, Paulus JK, Raman G, Wong JB, Steyerberg EW, Rijnbeek PR, Kent DM, van Klaveren D. Predictive approaches to heterogeneous treatment effects: a scoping review. BMC Med Res Methodol 2020;20:264. [PMID: 33096986 DOI: 10.1186/s12874-020-01145-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
19 Honig G, Heller C, Hurtado-Lorenzo A. Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2020;26:1451-62. [PMID: 32812036 DOI: 10.1093/ibd/izaa210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
20 Wiley C. Data Sharing: An Analysis of Medical Faculty Journals and Articles. Science & Technology Libraries 2021;40:104-15. [DOI: 10.1080/0194262x.2020.1781740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Dunn AG, Bourgeois FT. Is it time for computable evidence synthesis? J Am Med Inform Assoc 2020;27:972-5. [PMID: 32337600 DOI: 10.1093/jamia/ocaa035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Barrett JS. Perspective on Data-Sharing Requirements for the Necessary Evolution of Drug Development. J Clin Pharmacol 2020;60:688-90. [PMID: 32222078 DOI: 10.1002/jcph.1607] [Reference Citation Analysis]
23 Sim I, Stebbins M, Bierer BE, Butte AJ, Drazen J, Dzau V, Hernandez AF, Krumholz HM, Lo B, Munos B, Perakslis E, Rockhold F, Ross JS, Terry SF, Yamamoto KR, Zarin DA, Li R. Time for NIH to lead on data sharing. Science 2020;367:1308-9. [DOI: 10.1126/science.aba4456] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
24 Borysowski J, Wnukiewicz-Kozłowska A, Górski A. Legal regulations, ethical guidelines and recent policies to increase transparency of clinical trials. Br J Clin Pharmacol 2020;86:679-86. [PMID: 32017178 DOI: 10.1111/bcp.14223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020;368:l7078. [PMID: 32024657 DOI: 10.1136/bmj.l7078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
26 Zhang AD, Ross JS. Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation. J Law Med Ethics 2019;47:393-5. [PMID: 31560627 DOI: 10.1177/1073110519876170] [Reference Citation Analysis]
27 Mayo-Wilson E, Fusco N, Hong H, Li T, Canner JK, Dickersin K. Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. Trials 2019;20:553. [PMID: 31488200 DOI: 10.1186/s13063-019-3581-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
28 Miller J, Ross JS, Wilenzick M, Mello MM. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ 2019;366:l4217. [PMID: 31292127 DOI: 10.1136/bmj.l4217] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
29 Sajatovic M, Eyler LT, Rej S, Almeida OP, Blumberg HP, Forester BP, Forlenza OV, Gildengers A, Mulsant BH, Strejilevich S, Tsai S, Vieta E, Young RC, Dols A. The Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD) project: Understanding older-age bipolar disorder by combining multiple datasets. Bipolar Disord 2019;21:642-9. [PMID: 31081573 DOI: 10.1111/bdi.12795] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]